Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment

By Ben Glickman

Roche Group-member Genentech said Thursday it had received regulatory approval for its treatment for patients with an early-stage form of lung cancer.

The South San Francisco, Calif.-based company said that the U.S. Food and Drug Administration had approved Alecensa in treating patients with anaplastic lymphoma kinase-positive non-small cell lung cancer who have already had tumor resection.

Alecensa is currently approved as a first- and second-line treatment for ALK-positive metastatic non-small cell lung cancer, the company said. In February, Roche reported U.S. sales of Alecensa of 467 million Swiss francs ($511.8 million).

The company said the approval was based on results from a Phase 3 study, which showed that Alecensa reduced risk of disease recurrence or death by 76%, as compared with platinum-based chemotherapy.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

April 18, 2024 18:03 ET (22:03 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.